StageAcquired | Acquired
About Receptor Biologix
Receptor BioLogix, Inc. is a biopharmaceutical company focused on the development and commercialization of a newly discovered class of protein therapeutics called Intron Fusion Proteins (IFP) to treat cancer, autoimmune, metabolic and other diseases.
Missing: Receptor Biologix's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Receptor Biologix's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Receptor Biologix
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Receptor Biologix is included in 1 Expert Collection, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Receptor Biologix Frequently Asked Questions (FAQ)
When was Receptor Biologix founded?
Receptor Biologix was founded in 2003.
Where is Receptor Biologix's headquarters?
Receptor Biologix's headquarters is located at 3350 West Bayshore Road, Palo Alto.
What is Receptor Biologix's latest funding round?
Receptor Biologix's latest funding round is Acquired.
How much did Receptor Biologix raise?
Receptor Biologix raised a total of $39.6M.
Who are the investors of Receptor Biologix?
Investors of Receptor Biologix include Symphogen, EW Healthcare Partners, New Science Ventures, Northwest Technology Ventures, MedImmune Ventures and 5 more.
Who are Receptor Biologix's competitors?
Competitors of Receptor Biologix include Acceleron Pharma, Bird Rock Bio, AM-Pharma, Array Biopharma, Threshold Pharmaceuticals and 13 more.
Compare Receptor Biologix to Competitors
AM-Pharma is a biopharmaceutical company that focuses on the development of recombinant Alkaline Phosphatase for clinical use.
Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating scientific knowledge into new medicines. The company's understanding of the role of the tissue factor in angiogenesis, inflammation, and malignancies has led it to a new approach to developing therapies for devastating diseases such as macular degeneration and cancer.
Aphios is a clinical stage biotechnology company. It develops technology platfroms to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic safety. Based on these platforms, the company develops therapeutics to prevent disease, maintain health, and treat chronic diseases, including cancers and supportive care, infectious diseases such as HIV/AIDS, influenza and COVID-19. The company was founded in 2018 and is based in Woburn, Massachusetts.
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
ACUREON Pharmaceuticals is a United States biopharmaceutical company primarily focused on specialty therapeutics to improve patient outcomes in the hospital areas of Infectious Diseases, Transplant, and ICU. To address the needs of the market, Acureon Pharma is focused on exploring opportunities that selectively acquire and enhance the market potential of commercially available therapeutics and late-stage development drugs. The company is located in the western suburbs of Philadelphia.
Limerick BioPharma is developing compounds that per the company when used adjunctively with both marketed and investigational drugs improve drug side effect profiles and clinical outcomes. By activating cellular transport pumps to redistribute drugs away from organs and tissues where they have adverse effects, the company's compounds aim to minimize toxic side effects at non-targeted vulnerable organs and tissues while maintaining or enhancing a drug's desired effects. Per the company, Limerick's pipeline molecules are applicable to a broad range of therapeutic drug classes including immunosuppressants, opioids, immunomodulators, selective estrogens receptor modulators, and psychotropics. In the monotherapy setting, Limerick is developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia via a mechanism related to reverse cholesterol transport.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.